Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Héctor Ortega, Mark C. Liu, Ian Pavord et al. · New England Journal of Medicine · 2014 · 2.3K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity

Toyohide Shinkawa, Kazuyasu Nakamura, Naoko Yamane et al. · Journal of Biological Chemistry · 2003 · 1.4K citations · Full text

Life Sciences, Biochemistry, Immunology +17

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Immunology, Pharmacology +17

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Michael E. Wechsler, Praveen Akuthota, David Jayne et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

Matthieu Groh, Christian Pagnoux, Chiara Baldini et al. · European Journal of Internal Medicine · 2015 · 480 citations · Full text

Medicine, Internal Medicine, Pathology +13